Recce Pharmaceuticals raise to progress advanced anti-infective
Recce Pharmaceuticals (ASX:RCE) has raised $11 million to continue developing its late-stage drug candidate, anti-infective, R327
| Change | ||
| S&P/ASX Sm. Ords. | |||
| All Ordinaries | |||
| S&P/ASX 100 |